You are here

  • Home
  • Archive
  • Volume 15, Issue Suppl 3
  • Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) compar…

Article metrics

Article menu
Download PDFPDF
Articles
Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

 

Online download statistics by month:

Online download statistics by month: December 2018 to March 2023

AbstractFullPdf
Dec 2018200
Feb 20191201
Mar 2019400
Apr 2019200
May 2019800
Jun 20191100
Jul 2019400
Aug 2019800
Oct 2019600
Nov 2019200
Dec 20191200
Jan 2020800
Feb 2020601
Mar 20202200
Apr 20201600
May 20201200
Jun 20201400
Jul 20201000
Aug 2020200
Sep 2020600
Oct 2020802
Nov 2020400
Dec 20203000
Jan 2021400
Feb 20211400
Mar 2021400
Apr 2021400
May 2021800
Oct 20211200
Nov 2021600
Dec 20211402
Jan 20221800
Feb 20221600
Mar 20221201
Apr 20221000
May 20225800
Jun 20223800
Jul 20222400
Aug 20226602
Sep 20225400
Oct 20225200
Nov 20223400
Dec 20222600
Jan 20231600
Feb 202311000
Mar 20231000
Total81909